High-Grade Salivary Gland Ductal Carcinoma With Unusual EGFR Amplification Responsive to Afatinib

Related Experiment Video

Updated: Oct 5, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.1K

Jiun-I Lai1,2, Abhinav K Reddy3, Justin Y Newberg3

  • 1National Yang-Ming University, Taipei, Republic of China.

JCO Precision Oncology
|February 1, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Related Experiment Videos

Last Updated: Oct 5, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.1K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K

Articles linked to this work by shared authors, journal, and citation graph.

NeoGen-BC: A synergistic framework combining generative protein language models and multi-window deep learning for designing shared neoantigens in breast cancer.

Biochemical and biophysical research communications·2026

Prevalence of High Tumor Mutational Burden Among Pediatric Patients With Solid Tumors.

Pediatric hematology and oncology·2026

Nicotine drives lung cancer progression by suppressing cuproptosis through the LIAS-DLAT axis and promoting M2 macrophage polarization.

Free radical biology & medicine·2026

2025 Update of the Taiwan Expert Consensus on Hormone Receptor-Positive Metastatic Breast Cancer Management.

Journal of breast cancer·2026

Pan-cancer analysis identifies immunoproteasome as the predominant survival-associated component of antigen processing machinery.

Translational oncology·2026

MEK inhibitor cobimetinib increases calreticulin and induces immune modulation in TNBC.

Journal of molecular medicine (Berlin, Germany)·2026

Genomic Landscape of Gastroenteropancreatic Neuroendocrine Neoplasms Using Panel Sequencing.

JCO precision oncology·2026

PIK3CA Mutations in Advanced or Recurrent Endometrial Cancer: An Exploratory Molecular Profiling From the Phase II MITO END-3 Study.

JCO precision oncology·2026

Plasma-Derived Genomic Instability Status and Rucaparib Outcomes in Metastatic Castration-Resistant Prostate Cancer: TRITON2.

JCO precision oncology·2026

Cobimetinib + Vemurafenib in Patients With BRAF V600E-Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study.

JCO precision oncology·2026

Medulloblastoma Spatial Transcriptomics Reveals Tumor Microenvironment Heterogeneity With High-Density Progenitor Cell Regions Correlating With High-Risk Disease.

JCO precision oncology·2026

Genomic Landscape and Clinical Actionability of Skin Adnexal Carcinomas.

JCO precision oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us